CytoMed Total Current Liabilities vs Intangible Assets Analysis

Stocks . USA . 
Stock . CytoMed Therapeutics Limited
GDTC Stock   2.29  0.67  22.64%   
CytoMed Therapeutics financial indicator trend analysis is way more than just evaluating CytoMed Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether CytoMed Therapeutics is a good investment. Please check the relationship between CytoMed Therapeutics Total Current Liabilities and its Intangible Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Total Current Liabilities vs Intangible Assets

Total Current Liabilities vs Intangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of CytoMed Therapeutics Total Current Liabilities account and Intangible Assets. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between CytoMed Therapeutics' Total Current Liabilities and Intangible Assets is -0.52. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Intangible Assets in the same time period over historical financial statements of CytoMed Therapeutics Limited, assuming nothing else is changed. The correlation between historical values of CytoMed Therapeutics' Total Current Liabilities and Intangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of CytoMed Therapeutics Limited are associated (or correlated) with its Intangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Intangible Assets has no effect on the direction of Total Current Liabilities i.e., CytoMed Therapeutics' Total Current Liabilities and Intangible Assets go up and down completely randomly.

Correlation Coefficient

-0.52
Relationship DirectionNegative 
Relationship StrengthVery Weak

Total Current Liabilities

Total Current Liabilities is an item on CytoMed Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of CytoMed Therapeutics Limited are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.
Most indicators from CytoMed Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into CytoMed Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
The current year's Issuance Of Capital Stock is expected to grow to about 13.7 M, whereas Tax Provision is forecasted to decline to 630.58.
 2022 2023 2024 2025 (projected)
Other Operating Expenses1.4M3.2M3.7M3.9M
Depreciation And Amortization291.8K77.5K69.7K66.2K

CytoMed Therapeutics fundamental ratios Correlations

Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Good Will
Common Stock Shares Outstanding
Short Term Investments
Non Current Liabilities Total
Inventory
Other Current Assets
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Total Assets
-0.230.780.040.98-0.67-0.85-0.96-0.910.661.00.230.991.00.99-0.380.88-0.49-0.73-0.660.740.181.0-0.14-0.811.0
Short Long Term Debt Total
-0.23-0.280.96-0.42-0.19-0.280.43-0.120.13-0.22-0.82-0.18-0.23-0.21-0.690.01-0.73-0.490.860.450.88-0.191.0-0.28-0.19
Other Current Liab
0.78-0.28-0.040.77-0.71-0.65-0.82-0.770.360.790.350.810.790.820.020.89-0.22-0.51-0.640.61-0.070.78-0.21-0.720.8
Total Current Liabilities
0.040.96-0.04-0.16-0.4-0.520.17-0.390.290.05-0.780.090.040.06-0.790.26-0.87-0.710.690.670.950.080.98-0.520.08
Total Stockholder Equity
0.98-0.420.77-0.16-0.57-0.73-0.98-0.820.610.980.390.950.980.97-0.210.81-0.3-0.58-0.790.59-0.020.97-0.34-0.70.97
Net Tangible Assets
-0.67-0.19-0.71-0.4-0.570.80.580.77-0.18-0.680.27-0.75-0.68-0.740.5-0.690.570.730.28-0.72-0.48-0.69-0.250.7-0.71
Property Plant And Equipment Net
-0.85-0.28-0.65-0.52-0.730.80.730.93-0.72-0.860.27-0.89-0.85-0.850.7-0.860.830.950.24-0.96-0.59-0.87-0.360.89-0.85
Net Debt
-0.960.43-0.820.17-0.980.580.730.83-0.6-0.96-0.36-0.96-0.97-0.960.14-0.840.280.560.8-0.60.06-0.960.350.71-0.95
Retained Earnings
-0.91-0.12-0.77-0.39-0.820.770.930.83-0.66-0.910.05-0.93-0.91-0.920.52-0.930.720.90.36-0.91-0.45-0.92-0.210.97-0.93
Accounts Payable
0.660.130.360.290.61-0.18-0.72-0.6-0.660.67-0.040.640.660.59-0.460.69-0.64-0.69-0.20.740.30.670.2-0.670.63
Cash
1.0-0.220.790.050.98-0.68-0.86-0.96-0.910.670.210.991.00.99-0.380.88-0.49-0.74-0.660.740.181.0-0.14-0.811.0
Non Current Assets Total
0.23-0.820.35-0.780.390.270.27-0.360.05-0.040.210.130.220.210.640.140.610.38-0.64-0.33-0.750.19-0.820.080.21
Non Currrent Assets Other
0.99-0.180.810.090.95-0.75-0.89-0.96-0.930.640.990.130.990.99-0.390.89-0.52-0.76-0.640.770.210.99-0.09-0.820.98
Cash And Short Term Investments
1.0-0.230.790.040.98-0.68-0.85-0.97-0.910.661.00.220.990.99-0.380.88-0.49-0.73-0.660.740.181.0-0.14-0.811.0
Net Receivables
0.99-0.210.820.060.97-0.74-0.85-0.96-0.920.590.990.210.990.99-0.370.89-0.48-0.74-0.650.740.20.99-0.13-0.821.0
Good Will
-0.38-0.690.02-0.79-0.210.50.70.140.52-0.46-0.380.64-0.39-0.38-0.37-0.320.910.81-0.34-0.7-0.93-0.41-0.730.54-0.4
Common Stock Shares Outstanding
0.880.010.890.260.81-0.69-0.86-0.84-0.930.690.880.140.890.880.89-0.32-0.58-0.8-0.430.870.250.890.09-0.930.89
Short Term Investments
-0.49-0.73-0.22-0.87-0.30.570.830.280.72-0.64-0.490.61-0.52-0.49-0.480.91-0.580.94-0.31-0.9-0.91-0.52-0.780.77-0.51
Non Current Liabilities Total
-0.73-0.49-0.51-0.71-0.580.730.950.560.9-0.69-0.740.38-0.76-0.73-0.740.81-0.80.94-0.01-0.98-0.77-0.76-0.570.92-0.76
Inventory
-0.660.86-0.640.69-0.790.280.240.80.36-0.2-0.66-0.64-0.64-0.66-0.65-0.34-0.43-0.31-0.01-0.040.58-0.630.810.17-0.62
Other Current Assets
0.740.450.610.670.59-0.72-0.96-0.6-0.910.740.74-0.330.770.740.74-0.70.87-0.9-0.98-0.040.670.760.53-0.940.76
Total Liab
0.180.88-0.070.95-0.02-0.48-0.590.06-0.450.30.18-0.750.210.180.2-0.930.25-0.91-0.770.580.670.210.91-0.530.22
Total Current Assets
1.0-0.190.780.080.97-0.69-0.87-0.96-0.920.671.00.190.991.00.99-0.410.89-0.52-0.76-0.630.760.21-0.11-0.831.0
Short Term Debt
-0.141.0-0.210.98-0.34-0.25-0.360.35-0.210.2-0.14-0.82-0.09-0.14-0.13-0.730.09-0.78-0.570.810.530.91-0.11-0.36-0.1
Intangible Assets
-0.81-0.28-0.72-0.52-0.70.70.890.710.97-0.67-0.810.08-0.82-0.81-0.820.54-0.930.770.920.17-0.94-0.53-0.83-0.36-0.84
Common Stock
1.0-0.190.80.080.97-0.71-0.85-0.95-0.930.631.00.210.981.01.0-0.40.89-0.51-0.76-0.620.760.221.0-0.1-0.84
Click cells to compare fundamentals

CytoMed Therapeutics Account Relationship Matchups

High Positive Relationship

Cash
+ 1.0
Total Assets
Cash And Short Term Investments
+ 1.0
Total Assets
Total Current Assets
+ 1.0
Total Assets
Common Stock
+ 1.0
Total Assets
Short Term Debt
+ 1.0
Short Long Term Debt Total
Cash And Short Term Investments
+ 1.0
Cash

High Negative Relationship

Other Current Assets
- 0.98
Non Current Liabilities Total
Net Debt
- 0.98
Total Stockholder Equity
Cash And Short Term Investments
- 0.97
Net Debt
Total Current Assets
- 0.96
Net Debt
Net Receivables
- 0.96
Net Debt
Non Currrent Assets Other
- 0.96
Net Debt

CytoMed Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets2.9M4.5M3.9M12.4M14.2M14.9M
Short Long Term Debt Total2.3M2.4M3.1M448.0K515.2K489.5K
Other Current Liab326.7K176.1K400.3K643.7K740.2K411.8K
Total Current Liabilities2.1M2.2M3.1M716.9K824.5K783.3K
Total Stockholder Equity359.6K1.9M436.0K8.5M9.8M10.3M
Property Plant And Equipment Net1.7M1.8M1.8M1.6M1.4M1.5M
Net Debt1.6M551.6K2.0M(8.5M)(7.7M)(7.3M)
Retained Earnings(2.3M)(3.7M)(6.1M)(9.3M)(8.4M)(8.0M)
Accounts Payable14.3K34.2K10.9K24.6K28.3K21.2K
Cash668.8K1.9M1.2M9.0M10.3M10.9M
Non Current Assets Total1.8M2.1M2.0M2.3M2.6M2.3M
Non Currrent Assets Other(1.8M)(2.1M)(2.0M)546.7K628.7K660.1K
Cash And Short Term Investments668.8K1.9M1.2M9.0M10.3M10.9M
Net Receivables9.1K3.9K42.8K204.7K235.5K247.2K
Common Stock Shares Outstanding5.9M6.9M7.9M10.6M12.2M8.1M
Short Term Investments32.9K11.3K11.6K47.8K43.0K30.0K
Liabilities And Stockholders Equity2.9M4.5M3.9M12.4M14.2M14.9M
Non Current Liabilities Total464.0K410.0K353.3K407.8K367.0K361.6K
Inventory181.6K319.1K428.0K(204.7K)(184.3K)(175.1K)
Other Current Assets571.7K763.7K856.6K896.8K1.0M688.6K
Other Stockholder Equity(6.3K)1.1M(94.7K)(32.6K)(29.3K)(27.9K)
Total Liab2.5M2.6M3.4M1.1M1.3M2.3M
Total Current Assets1.1M2.4M1.9M10.1M11.6M12.2M
Accumulated Other Comprehensive Income(6.3K)(22.9K)(94.7K)(108.7K)(97.8K)(93.0K)
Short Term Debt1.8M2.0M2.8M40.3K46.3K44.0K
Intangible Assets33.9K23.4K13.7K12.1K10.9K19.0K
Common Stock2.6M4.8M6.6M18.0M20.7M21.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
BTCBitcoin
TRXTRON
BNBBinance Coin
When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:
How To Invest In CytoMed
Details
Is CytoMed Stock a good investment?
Details
What is CytoMed Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in CytoMed Therapeutics Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.22)
Revenue Per Share
0.039
Quarterly Revenue Growth
(0.21)
Return On Assets
(0.17)
Return On Equity
(0.26)
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY